Tradestie Institutional Equity Comparison Engine

RLYB vs MXCT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RLYB Overall Edge

RLYB Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Rallybio Corporation Common Stock (RLYB) driven by superior Valuation, Momentum & Technical while MXCT counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, RLYB trades at N/M Forward P/E with -5050.9% operating margin (+0.0% YoY revenue) versus MXCT at N/M Forward P/E and -85.5% operating margin (+48.7% YoY). In options structure, RLYB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against MXCT sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner RLYB
RLYB N/M vs MXCT N/M Fwd P/E
Growth & Margin Winner MXCT
Op Margin -5050.9% vs -85.5% ยท YoY +0.0% vs +48.7%
Momentum & Technical Winner RLYB
1Y +2378.4% vs -19.4% ยท 52W Pos 88% vs 63%
Options & Structure Winner MXCT
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
RLYB NASDAQ
Rallybio Corporation Common Stock
Pharmaceutical Preparations
$15.47
-0.32% 1D
Market Cap $86.9M
1M Return -5.67%
1Y Return +2378.37%
Forward P/E N/M
Unified AI Score
63.0 / 100 BUY
Tech 81.0 Fund 63.0 Flow 50.0 Mom 64.0
MXCT NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
1M Return -4.2%
1Y Return -19.41%
Forward P/E N/M
Unified AI Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RLYB +2378.37% MXCT -19.41% Spread: +2397.78 pp (RLYB Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period RLYB Revenue MXCT Revenue RLYB Op. Margin MXCT Op. Margin Margin Edge
FY2019 N/A $10M N/A -93.7% MXCT
FY2020 N/A $20M N/A -71.6% MXCT
FY2021 N/A $20M N/A -84.3% MXCT
FY2022 N/A $30M N/A -95.2% MXCT
FY2023 N/A $20M N/A -247.7% MXCT
FY2024 $0M $20M -9511.9% -230.5% MXCT
FY2025 $0M $20M -3853.6% -247.6% MXCT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RLYB (6) vs MXCT (3)
Institutional Metric RLYB MXCT Criterion Row Winner
Market Capitalization Scale $86.9M $132.2M Larger Scale MXCT
Trailing P/E Ratio Valuation 3.4x N/M Lower Multiple RLYB
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +48.7% Higher Growth MXCT
Operating Margin (TTM) Profitability -5050.9% -85.5% Higher Margin MXCT
Net Profit Margin Profitability 6177.4% -81.4% Higher Margin RLYB
Return on Equity (ROE) Capital Efficiency 34.5% -16.9% Higher ROE RLYB
52-Week Range Position Momentum 88% ($1โ€“$18) 63% ($1โ€“$2) Stronger Trend RLYB
Beta / 30D Volatility Risk Regime 0.37ฮฒ ยท 24% Vol 1.19ฮฒ ยท 96% Vol Lower Realized Risk RLYB
Unified Institutional Score Composite Signal 63.0 / 100 (BUY) 41.7 / 100 (SELL) Higher Composite RLYB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RLYB vs MXCT Buy Guide
RLYB UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live RLYB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MXCT UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MXCT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RLYB nor MXCT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.